Replimune Reports Promising Clinical Data for RP1 Plus Nivolumab at ASCO 2025, Highlighting Robust Responses and Safety Profile

Replimune Group presented data at ASCO 2025 for RP1 combined with nivolumab in melanoma patients who had failed anti-PD-1 treatment, demonstrating a 32.9% objective response rate in the IGNYTE clinical trial. Deep injections into visceral organs showed higher response rates compared to superficial injections, resulting in tumor reductions in both injected and non-injected lesions, while maintaining a favorable safety profile. Biosafety analysis confirmed RP1 DNA typically remains localized to the injection site, with standard disinfection procedures deemed sufficient for clean-up.

Analysis

Replimune Group (REPL) presented encouraging data from its IGNYTE clinical trial at the ASCO 2025 meeting, showcasing RP1 in combination with nivolumab for anti-PD-1 failed melanoma patients. The combination achieved an objective response rate (ORR) of 32.9% and a complete response rate of 15.0%, with landmark overall survival rates reported at 75.3% for one year, 63.3% for two years, and 54.8% for three years, and median overall survival not yet reached. A significant finding was the numerically higher ORR for deep/visceral injections (40.9%-42.9%) compared to superficial-only injections (29.8%), indicating potent responses in both injected and non-injected lesions and supporting systemic activity. The treatment maintained a favorable safety profile, even with direct injections into the liver and lung, and a biosafety analysis confirmed RP1 DNA is primarily localized, manageable with standard disinfection. Despite these positive clinical signals, the 32.9% ORR may face scrutiny for this advanced patient population, and as a clinical-stage company, Replimune carries inherent risks related to ongoing trial progression and regulatory approvals, as highlighted in its forward-looking statements. Insider trading activity over the past six months has consisted exclusively of seven sales, including by the CEO, which warrants investor attention. Institutional ownership changes were mixed, with 83 firms adding to positions (notably Marshall Wace and Rosalind Advisors) and 81 decreasing (including complete exits by Norges Bank and ExodusPoint). Analyst sentiment remains positive, with two recent buy ratings and a median price target of $23.0.

Key Decisions for Investors

• Investors should evaluate the promising IGNYTE trial outcomes for RP1, particularly the higher efficacy of deep injections and strong survival data, while considering the 32.9% ORR in a difficult-to-treat melanoma cohort and the typical risks of a clinical-stage biotech.
• Closely monitor upcoming data on long-term efficacy and safety profiles, especially concerning deep visceral injections, as well as regulatory interactions, which will be critical catalysts for REPL.
• Consider the contrast between positive analyst ratings and some institutional accumulation against the backdrop of consistent insider selling and notable exits by other large funds when assessing risk and position sizing.
• Evaluate RP1's potential differentiation within the oncolytic immunotherapy market, given its demonstrated systemic anti-tumor response and favorable safety profile associated with deep visceral lesion injections.